EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers

Mari Hosonaga, Eri Habano, Hiromi Arakawa, Keika Kaneko, Takeshi Nakajima, Naomi Hayashi, Ippei Fukada, Akira Nakamura, Yurie Haruyama, Tetsuyo Maeda, Hitoshi Inari, Takayuki Kobayashi und 6 weitere

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01612-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2024. Verfasst von Mari Hosonaga und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. mari.hosonaga@jf…. Hauptthemen laut MEDLINE: Breast Neoplasms, Li-Fraumeni Syndrome, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Li-Fraumeni syndrome (LFS), a hereditary condition attributed to TP53 pathogenic variants,(PV), is associated with high risks for various malignant tumors, including breast cancer. Notably, individuals harboring TP53 PVs are more likely (67–83%) to develop HER2 + breast cancer than noncarriers (16–25%). In this retrospective study, we evaluated the associations between TP53 variants and breast cancer phenotype.

Methods

We conducted a retrospective review of the medical records of patients with LFS treated at a single institution and reviewed the literature on TP53 functions and the mechanisms underlying HER2 + breast cancer development in LFS.

Results

We analyzed data for 10 patients with LFS from 8 families. The median age at the onset of the first tumor was 35.5 years. Only case 2 met the classic criteria; this patient harbored a nonsense variant, whereas the other patients carried missense variants. We observed that 9 of 10 patients developed breast cancer. Immunohistochemical analyses revealed that 40% of breast cancers in patients with LFS were HR − /HER2 + . The median age at the onset of breast cancer was slightly younger in HR − /HER2 + tumors than in HR + /HER2 − tumors (31 years and 35.5 years, respectively).

Conclusions

The occurrence of HER2 + breast cancer subtype was 40% in our LFS case series, which is greater than that in the general population (16–25%). Some TP53 PVs may facilitate HER2-derived oncogenesis in breast cancer. However, further studies with larger sample sizes are warranted to clarify the oncogenic mechanisms underlying each subtype of breast cancer in TP53 PV carriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLi-Fraumeni SyndromeTumor Suppressor Protein p53AdultFemaleHumansGenetic Predisposition to DiseaseHeterozygoteErb-b2 Receptor Tyrosine KinasesRetrospective Studies

Stichwörter der Autor:innen

TP53Breast cancerHormone receptorHuman epidermal growth factor receptor 2Li-Fraumeni syndrome

Substanzen

Erb-b2 Receptor Tyrosine KinasesTumor Suppressor Protein p53ERBB2 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. mari.hosonaga@jfcr.or.jp.
  • Department of Clinical Genetic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Medical Ethics and Medical Genetics, Kyoto University, Graduate of School of Medicine, School of Public Health, Kyoto, 606-8501, Japan.
  • Division of Genomic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Department of Breast Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.

Zitieren

APA

Hosonaga, M., Habano, E., Arakawa, H., Kaneko, K., Nakajima, T., Hayashi, N., Fukada, I., Nakamura, A., Haruyama, Y., Maeda, T., Inari, H., Kobayashi, T., Nakashima, E., Ueno, T., Takano, T., Takahashi, S., Ohno, S., & Ueki, A. (2024). Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers. Breast Cancer. https://doi.org/10.1007/s12282-024-01612-3

Vancouver

Hosonaga M, Habano E, Arakawa H, Kaneko K, Nakajima T, Hayashi N, et al. Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers. Breast Cancer. 2024. doi:10.1007/s12282-024-01612-3

BibTeX
@article{Hosonaga2024,
  author = {Hosonaga, Mari and Habano, Eri and Arakawa, Hiromi and Kaneko, Keika and Nakajima, Takeshi and Hayashi, Naomi and Fukada, Ippei and Nakamura, Akira and Haruyama, Yurie and Maeda, Tetsuyo and Inari, Hitoshi and Kobayashi, Takayuki and Nakashima, Eri and Ueno, Takayuki and Takano, Toshimi and Takahashi, Shunji and Ohno, Shinji and Ueki, Arisa},
  title = {Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01612-3}
}
Kostenlos starten →